Neuland Laboratories Limited has informed the Exchange about General Updates
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts less than Nifty Smallcap 250 and 7.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported consolidated revenue from operations of Rs. 1,476.84 crore for FY25, down about 5.2% from Rs. 1,558.58 crore in FY24. Profit before exceptional items and tax fell sharply to Rs. 269.93 crore from Rs. 401.44 crore, a drop of nearly 33%, pointing to clear margin compression in the core API business. The company booked a one-time exceptional gain of Rs. 76.40 crore from transferring an investment property in Nanakramguda, Hyderabad through a perpetual lease, which lifted reported pre-tax profit to Rs. 346.33 crore and net profit to Rs. 260.11 crore (vs Rs. 300.08 crore). EPS stood at Rs. 202.74 vs Rs. 233.89. The Board recommended a final dividend of Rs. 12 per share (120%) and re-appointed Mr. Davuluri Saharsh Rao as Vice Chairman & Managing Director for five years. Statutory auditors MSKA & Associates issued an unmodified (clean) opinion on both standalone and consolidated results.
The sharp drop in core operating profit is a negative signal for shareholders, suggesting pricing pressure or cost headwinds in the API business, though it is partly cushioned by a one-off property gain. The 120% dividend is a positive return signal, but the underlying earnings weakness may weigh on the stock in the short term.